Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Galapagos is excited to meet you at #ATS2019 in Dallas, Friday May 17th – Wednesday May 22nd galapagosats2019.com/ Posters / Abstracts of interest Sunday May 19th, 09:15 - 11:15 12902 - Characterization of GLPG1205 in Mouse Fibrosis Models: A Potent and Selective Antagonist of GPR84 for Treatment of Idiopathic Pulmonary Fibrosis. Sunday May 19th, 14:15 - 16:15 9219 - Autotaxin Inhibitorsin IPF: Elucidation of a Novel Binding Mode for GLPG1690 A108 - Pathophysiology in Diffuse Parenchymal Lung Diseases. Tuesday May 21st, 09:15 - 16:15 9221 - Rationale, Design and Objectives of Two Phase III, Randomised, Placebo-Controlled Studies of GLPG1690, a Novel Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (ISABELA 1 and 2).
Galapagos: Update Isabela trials $GLPG The Netherlands (ISABELA2) added in clinicaltrialsregister.eu: www.clinicaltrialsregister.eu/ctr-sea... Planned number of subjects to be included: 43 Number of sites anticipated in Member State concerned: 6twitter.com/lama_daila/status/1129673...
Updates fase 3 IPF studies, gerund door Galapagos, zijn per 20 mei gemeld. In totaal nu 86 klinieken open, waarvan 4 in Nederland.Netherlands Martini Ziekenhuis Recruiting Groningen, Netherlands, 9700 RM Zuyderland Medisch Centrum Recruiting Heerlen, Netherlands, 6419 PC St. Antonius Ziekenhuis Recruiting Nieuwegein, Netherlands, 3425 CM Erasmus MC Recruiting Rotterdam, Netherlands, 3015 GD Verder laat ik het graag aan Lama met zijn strakke overzicht. Met deze snelheid +200 klinieken open in (na)zomer 2019.
Inderdaad, hier mijn aangepast overzicht met 84 centers.
Lama Daila schreef op 20 mei 2019 20:51 :
Inderdaad, hier mijn aangepast overzicht met 84 centers.
Mooi! 1 aanvulling: Bij ISABELA2 zijn er nog 2 Duitse klinieken open gegaan.
pe26 schreef op 20 mei 2019 22:17 :
[...]
Mooi!
1 aanvulling:
Bij ISABELA2 zijn er nog 2 Duitse klinieken open gegaan.
Inderdaad, die was ik nog vergeten. Ik zal ze nog opnemen. We zitten dus effectief aan 86 centers.
Galapagos heeft groot uitgepakt in Dallas op het ATS 2019 congres. Meerdere abstracts en aantal Guru sessies. Grote opkomst. Verder hebben zij programma aangekondigd via galapagosats2019.com/ Best opvallend dat op officiële website er geen persbericht is geweid aan abstracts etc. Wel is het als scientific meeting vermeld. Enorme blockbuster potentie voor GLPG1690 in IPF/Ssc. Daarnaast nog mogelijke toekomstige combi-opties met andere Galapagos moleculen voor IPF etc.
MIsschien al gezien door anderen maar Galapagos schakelt dochter Fidelta sinds 12 december 2018 in voor fibrosis discovery onderzoek:fidelta.eu/fidelta-announces-drug-dis... Fidelta announces drug discovery agreement with Galapagos 12. December 2018. 12th December 2018 Fidelta announces drug discovery agreement with Galapagos Zagreb, Croatia, 12th – Fidelta Ltd is pleased to announce that it has signed an integrated drug discovery agreement with Galapagos based on Fidelta’s macrocyclic platform. Under the terms of the agreement, Galapagos will leverage Fidelta’s extensive expertise in macrocyclic drug discovery to further strengthen its fibrosis portfolio. Adrijana Vinter, Managing Director, Fidelta commented, “Today’s news is a recognition of our know-how in macrocyclic drug discovery, and we are excited to support Galapagos’ efforts in fibrotic research.” “Fidelta is an undisputed leader in macrocyclic drug discovery, and this transaction could bring considerable new angles to our rapidly expanding efforts in fibrotic research,” said Dr. Piet Wigerinck, Chief Scientific Officer of Galapagos. About Fidelta Fidelta, a wholly-owned subsidiary of Galapagos NV, is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development. Fidelta has developed a new macrocyclic drug discovery platform, FideltaMacroTM. Fidelta’s objective is to deliver efficacious, safe and differentiated pre-clinical candidates to its clients. For more information, visit www.fidelta.eu. More information: Fidelta d.o.o. Adrijana Vinter, Managing Director Tel: +385 1 8886395fidelta@glpg.com ----- Dit is bij mijn weten niet door Galapagos gepubliceerd, maar geeft wel aan dat Galapagos alles in het werk stelt om de fibrosis franchise uit te bouwen en geeft wat extra kleur aan het twitter bericht van Onno: "Lets build that franchise" van vlak voor de Dallas conferentie.
Lama Daila schreef op 22 mei 2019 23:16 :
Poster P1036 in PDF-kwaliteit:
users.telenet.be/LamaDaila/Galapagos/... Iedereen met interesse in IPF en de Isabela trials zou naast bovenstaande poster ook volgend document eens grondig moeten lezen:bmjopenrespres.bmj.com/content/bmjres... Rationale, design and objectives of two phase III, randomised, placebo- controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
Conclusions GLPG1690, the first ATX inhibitor in clinical development for the treatment of IPF, will be evaluated in two parallel, identically designed, phase III studies (ISABELA 1 and 2) with a 52-week minimum treatment period. For the first time, GLPG1690 will be assessed as an addition to SOC, reflecting potential real-world use. The studies will provide a wide range of clinically relevant data, building on positive clinical findings to date. Positive results may ultimately mean that GLPG1690, alone or in combination, will become a much-needed new treatment option for patients with IPF.GLPG1690 is still wholly owned by Galapagos. Design of the ISABELA 1 and 2 studies. D, day; EoSA, end-of-study assessment; EoST, end-of-study treatment; FU, follow-up; qd, once daily; V, visit; W, week.
Clinical studies of GLPG 1690 and BG00011 pulmonaryfibrosisnews.com/forums/foru...
[quote alias=harvester id=11623971 date=201905300008] Clinical studies of GLPG 1690 and BG00011 pulmonaryfibrosisnews.com/forums/foru... [/quote: Ene Danny schrijft: Both of these studies are recruiting right now, One at the Cleveland Clinic and one at the University of Michigan. I have a pulmonologist at each hospital and will be getting into one of them. Both drugs did very well in original testing and both almost stop signals that cause scarring and minor or no side effects on healthy volunteers. Much better then OFEV and Esbriet! If anyone can get in on one you should do it. I will be doing the GLPG 1690 at U of M
Griekenland is nog toegevoegd op clinicaltrialsregister.eu: Gepland aantal patienten: 37 Gepland aantal centers: 5 Merk op dat voor Spanje en Frankrijk blijkbaar alle geplande centers al recruiting zijn. In bijlage nog eens het aangepaste overzicht.
Qua chemie de concurrent met min of meer hetzelfde werkingsmechanisme:Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis Postive Interim Results from Ongoing Phase 1 Trial Presented at ATS 2019 May 20, 2019 - Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on BBT-877, a drug candidate for treatment of idiopathic pulmonary fibrosis (IPF), at the American Thoracic Society International Conference (ATS 2019) held in Dallas, Texas from May 17-22. Interim pharmacokinetic and safety results from the randomized, double-blind, placebo-controlled, Phase I study were included in a poster “BBT-877, a potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis” presented on May 19, during the Pathophysiology in Diffuse Parenchymal Lung Diseases poster session. In the single-ascending dose (SAD) portion of the study, plasma concentrations of BBT-877 increased with dose in a dose-proportional manner. All doses demonstrated safety and tolerability, with only mild adverse events (AEs) and no serious AEs. Furthermore, there were no clinically related findings in safety assessments of the study, such as electrocardiogram, vital sign, laboratory biochemical/hematological profile, and urinalysis results. “We remain highly focused on the clinical development of BBT-877,” said Gwang-hee Lee, PhD, Vice President, Head of Translational Research at Bridge Biotherapeutics. “BBT-877 has shown potential as a best-in-class ATX inhibitor for treatment of IPF with favorable results in the first-in-human, clinical study. These findings reinforce our continued collaborations with world-class pulmonologists specializing in IPF.” The Phase I study of BBT-877 (ClinicalTrials.gov Identifier: NCT03830125) is expected to be finalized by August 2019, and a multinational Phase II study is planned to be conducted in the U.S., Canada, Australia, and multiple countries in Europe and Asia. Preclinical research of BBT-877 has demonstrated its potency and in vivo efficacy as an ATX inhibitor and best-in-class potential. These interim clinical data contribute to the BBT-877 safety and tolerability demonstrated to date and support the continued development of BBT-877 for treatment of IPF. The original file of the poster presented at the ATS 2019 is available at bridgebiorx.com/upload/pdf/71eba4a326...
Nieuwe update van de ISABELA trials op clinicaltrials. 107 centers recruiting momenteel. Nieuwe landen: België, Chili, UK en Zuid-Afrika.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)